Aptinyx to Report Second Quarter 2019 Financial Results on Monday, August 12, 2019
August 05 2019 - 8:03AM
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical
company developing transformative therapies for the treatment of
brain and nervous system disorders, today announced that the
company will host a conference call and live webcast on Monday,
August 12 2019, at 8:00 A.M. ET to report second quarter 2019
financial results and to discuss recent business highlights.
To access the live conference call, please dial 1-866-930-5579
(domestic) or 1-409-216-0606 (international) and refer to
conference ID 9072524. A live audio webcast of the event will be
available on the Investors & Media section of Aptinyx’s website
at https://ir.aptinyx.com. A replay of the webcast will be
archived on Aptinyx’s website for 30 days following the event.
About Aptinyx
Aptinyx Inc. is a clinical-stage biopharmaceutical company
focused on the discovery, development, and commercialization of
proprietary synthetic small molecules for the treatment of brain
and nervous system disorders. Aptinyx has a platform for discovery
of novel compounds that work through a unique mechanism to modulate
– rather than block or over-activate – NMDA receptors and enhance
synaptic plasticity, the foundation of neural cell communication.
The company has three product candidates in clinical development in
central nervous system indications, including chronic pain,
post-traumatic stress disorder, and cognitive impairment associated
with Parkinson’s disease. Aptinyx is also advancing additional
compounds from its proprietary discovery platform, which continues
to generate a rich and diverse pipeline of small-molecule NMDA
receptor modulators with the potential to treat an array of
neurologic disorders. For more information, visit
www.aptinyx.com.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the company’s business plans and objectives, therapeutic effects of
the company’s product candidates, expectations regarding the
design, implementation, timing, and success of its current and
planned clinical studies, and expectations regarding its uses and
sufficiency of capital. Risks that contribute to the uncertain
nature of the forward-looking statements include: the success,
cost, and timing of the company’s product candidate development
activities and planned clinical studies; the company’s ability to
execute on its strategy; positive results from a clinical study may
not necessarily be predictive of the results of future or ongoing
clinical studies; regulatory developments in the United States and
foreign countries; as well as those risks and uncertainties set
forth in the company’s most recent Annual Report on Form 10-K and
subsequent filings with the Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Aptinyx undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
Investor & Media Contact:Nick SmithAptinyx
Inc.ir@aptinyx.com or corporate@aptinyx.com847-871-0377
Source: Aptinyx Inc.
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Sep 2023 to Sep 2024